<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>10</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4959</FirstPage>
			<LastPage>4962</LastPage>
			<ELocationID EIdType="pii">26974</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>The objective of this retrospective study was to investigate prognostic factors associated with survival ofpatients with extensive stage small cell lung cancer (ES-SCLC). Included were 200 patients admitted to theLiberation Army General Hospital with a diagnosis of ES-SCLC. The demographics of patients, diseasecharacteristics, pre-treatment biochemical parameters and therapeutic plan were assessed or evaluated.Univariate analysis found that second-line chemotherapy, radiotherapy, and no liver metastasis were associatedwith improved survival. Tumor response to first-line chemotherapy and normal initial hemoglobin levels werealso associated with a survival benefit (all P-values ≤ 0.0369). Multivariate Cox regression analysis indicatedthat liver metastasis and the total number of all chemotherapy cycles were independent prognostic factors ofsurvival. The morbidity risk in patients with liver metastasis was 2.52-fold higher than that in patients withoutliver metastasis (hazard ratio (HR)=2.52 (1.69-3.76); P&lt;0.0001). However, one unit increase in the total numberof chemotherapy cycles decreased the risk of death by 0.86-fold (HR=0.86 (0.80-0.92); P&lt;0.0001). Absence ofliver metastasis and ability of a patient to receive and tolerate multiple lines of chemotherapy were associatedwith longer survival.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">small cell lung cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">extensive stage</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognosis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">liver metastasis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26974_998c2eb428a67af15f3f72b213e3c229.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
